Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
Fernanda MoseleDepartment of Medical Oncology, Gustave Roussy, Villejuif, FranceJordi RemónDepartment of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, SpainJoaquı́n MateoClinical Research Program, Vall Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, SpainC. Benedikt WestphalenComprehensive Cancer Center Munich and Department of Medicine III, University Hospital, LMU Munich, Munich, GermanyFabrice BarlésiDepartment of Medical Oncology, Gustave Roussy, Villejuif, FranceMartijn P. LolkemaDepartment of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the NetherlandsNicola NormannoCell Biology and Biotherapy Unit, Istituto Nazionale Tumori, 'Fondazione G. Pascale' - IRCCS, Naples, ItalyAldo ScarpaARC-Net Research Centre and Department of Diagnostics and Public Health - Section of Pathology, University of Verona, Verona, ItalyMark E. RobsonBreast Medicine and Clinical Genetics Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USAFunda Meric‐BernstamDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USANikhil WagleDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USAAlbrecht StenzingerInstitute of Pathology, University Hospital Heidelberg, Heidelberg, GermanyJean-François BonastreDepartment of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, FranceAriane BayleDepartment of Medical Oncology, Gustave Roussy, Villejuif, France; Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, FranceStefan MichielsDepartment of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, FranceIvan BiècheDepartment of Genetics, Institut Curie, Paris Descartes University, Paris, FranceÉtienne RouleauCancer Genetic Laboratories, Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, FranceS. JezdicScientific and Medical Division, European Society for Medical Oncology, Lugano, SwitzerlandJ.-Y. DouillardScientific and Medical Division, European Society for Medical Oncology, Lugano, SwitzerlandJ.S. Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, USARodrigo DienstmannOncology Data Science Group, Molecular Prescreening Program, Vall d'Hebron Institute of Oncology, Barcelona, SpainFabrice AndréDepartment of Medical Oncology, Gustave Roussy, Villejuif, France; Inserm, Gustave Roussy Cancer Campus, UMR981, Villejuif, France; Paris Saclay University, Orsay, France. Electronic address: [email protected]
2020en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0